Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: An open multicenter prospective study

Journal of Gastroenterology

Volumn 39, Issue 12, 2004, Pages 1158-1164

  Fukuda, Yoshihiro ^a   Matsui, Toshiyuki ^b   Suzuki, Yasuo ^c   Kanke, Kazunari ^d   Matsumoto, Takayuki ^e,g   Takazoe, Masakazu ^f   Motoya, Satoshi ^h   Honma, Terasu ⁱ   Sawada, Koji ^a,j   Yao, Tsuneyoshi ^b   Shimoyama, Takashi ^a   Hibi, Toshifumi ^k  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f Kousei Chuo General Hospital   (Japan)

^g OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h Sapporo Kosei General Hospital   (Japan)

ⁱ NIIGATA UNIVERSITY   (Japan)

^j Fujimoto Hospital Medicine   (Japan)

^k KEIO UNIVERSITY   (Japan)

more..

Author keywords

Adsorptive apheresis; Crohn's disease; Granulocytes and monocytes; IBD questionnaire; IOIBD; Nutritional therapy

Indexed keywords

COMPLEMENT RECEPTOR; CORTICOSTEROID; FC RECEPTOR; MESALAZINE; METRONIDAZOLE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADSORPTION; APHERESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIET THERAPY; DISEASE ACTIVITY; ENTERITIS; FEMALE; GRANULOCYTE TRANSFUSION; HEALTH CARE ORGANIZATION; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPHOCYTE; MALE; MEDICAL INSTRUMENTATION; MONOCYTE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD COMPONENT REMOVAL; CHILD; CROHN DISEASE; FEMALE; GRANULOCYTES; HUMANS; MALE; MIDDLE AGED; MONOCYTES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 19944429890     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1465-z     Document Type: Article

References (34)

1. Allison MC, Dhillon AP, Lewis WG, Pounder RE, editors. Inflammatory bowel disease. London: Mosby; 1998. p. 15-95.
2. Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama T. Efficacy of nutritional therapy for active Crohn's disease. J Gastroenterol 1995;30(Suppl VIII):83-7.
3. Fernandez-Banares F, Cabre E, Gonzalez-Huix F, Gassull MA. Enteral nutrition as primary therapy in Crohn's disease. Gut 1994;35(Suppl):S55-9.
4. O'Keefe SJ. Nutrition and gastrointestinal disease. Scand J Gastroenterol (Suppl) 1996;220:52-9.
5. Tsujikawa T, Andoh A, Fujiyama Y. Enteral and parenteral nutrition therapy for Crohn's disease. Curr Pharm Des 2003;9:323-32.
6. Harris ML, Bayless TM. Dietary antigens as aggravating factors in Crohn's disease. Dig Dis Sci 1989;34:1613-4.
7. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92 (Suppl):5S-11S.
8. Miura S, Fujimori H, Koseki S, Hokari R. Mucosal immune system of the intestine (in Japanese with English abstract). Nippon Rinsho 1998;56:2228-34.
9. Powell JJ, Harvey RS, Ashwood P, Wolstencroft R, Gershwin ME, Thompson RP. Immune potentiation of ultrafine dietary particles in normal subjects and patients with inflammatory bowel disease. J Autoimmun 2000;14:99-105.
10. Sakurai T, Matsui T, Yao T, Takagi Y, Hirai F, Aoyagi K, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: A randomized, controlled trial comparing nutrient formulas. J Parenter Enteral Nutr 2002;26:98-103.
11. Furukawa H, Yamada M, Sakurai T. Enteral nutrition and total parenteral nutrition in Crohn's disease: Factors influencing induction of remission. Gastroenterol Jpn 1997;94:813-25.
12. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol 2002;97:803-23.
13. van Dullemen HM, van Deventer SJ, Hommes DW, Bijil HA, Woody J. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
14. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48-57.
15. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003;29: 185-202.
16. McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease. Morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991;86:489-93.
17. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000;6:21-33.
18. Meuret G, Bitzi A, Hammer B. Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology 1978;74:501-3.
19. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994;35:669-74.
20. Brannigan AE, O'Connell PR, Hurley H, O'Neill A, Brady HR, Fitzpatrick JM, et al. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 2000;13:361-6.
21. Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, et al. Adacolumn, an adsorptive carrier-based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48-59.
22. Hanai H, Watanabe F, Saniabadi A, Matsushita I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 2002; 47:2349-53.
23. Grisham MB, Yamada T. Neutrophils, nitrogen oxides and inflammatory bowel disease, neuro-immuno-physiology of the gastrointestinal mucosa. Ann NY Acad Sci 1992;664:103-15.
24. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker. Scand J Gastroenterol 1999; 34:500-4.
25. Tibble JA, Sigthorsson G, Bridger D, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
26. Hanai H, Watanabe F, Takeuchi K, Saniabadi A, Bjarnason I. Leucocyte adsorptive apheresis for the treatment of active ulcerative colitis: A prospective uncontrolled pilot study. Clin Gastroenterol Hepatol 2003;1:28-35.
27. Hiraishi K, Takeda Y, Shiobara N, Shibusawa H, Jimma F, Kashiwagi N, et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: An in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003;7:334-40.
28. Ohara M, Saniabadi AR, Kokuma S, Hirata I, Adachi M, Agishi T, et al. Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 1997;21:989-94.
29. Kashiwagi N, Hirata I, Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher 1998;2:134-41.
30. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's disease: A report on seven refractory patients. Am J Gastroenterol 2003;511-2.
31. de Dombal FT, Softley A. IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 1987;28:474-81.
32. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96.
33. Fuchigami T, Ohgushi H, Imamura K. Effects of total parenteral nutrition on colonic lesion in Crohn's disease: Radiographic and endoscopic studies. Gastroenterol Jpn 1982;17:52-9.
34. Kashiwagi N, Saniabadi A, Shimoyama T. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002; 47:1334-41.